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CASE REPORT
Familial amyloidotic polineuropathy and systemic lupus
AC Ferreira, F Carvalho and F Nolasco
Department of Nephrology, Centro Hospitalar de Lisboa Central, Hospital de Curry Cabral, Lisbon, Portugal
Familial amyloidotic polineuropathy is a genetic disorder, leading to systemic amyloid depos-
its, manifested as sensory-motor and autonomic neuropathy. In the Portuguese classical form,
the disease is evident at a young age, and causes death if no specific treatment is received.
Variability in penetrance, age of onset and clinical course has been published; environmental
and genetic factors are believed to contribute to this variability.
The authors report a case of a 51-year-old white female, with a medical history of acquired
angioedema, late-onset familial amyloidotic polineuropathy and systemic lupus erythematho-
sus. The authors consider that these associated diseases could modulate their
expression. Lupus (2012) 21, 1455–1458.
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Background
Portuguese familial amyloidotic polyneuropathy
(FAP) is a genetic autosomal dominant disorder,
caused by an amino acid substitution of methionine
for valine at position 30 (V30M) of the transthyr-
etin (TTR) molecule, leading to diﬀusely distribu-
ted amyloid deposits of ﬁbril protein in the
peripheral nervous system.1,2 Nevertheless, this
amino-acid substitution alone does not explain
penetrance, age of onset and clinical course of the
disease. In Portuguese variants, the incidence of
penetrance is high (80%), and the disease is evident
before the age of 40.2 The disease typically causes a
nerve length-dependent sensorimotor polyneurop-
athy, but potentially unmyelinated and small mye-
linated ﬁbres can also be involved. The symptoms
start in the lower extremities, with spontaneous
pains, numbness and loss of temperature sensations
that extend above the ankle level. Motor deﬁcit also
occurs, with loss of balance and stepping gait.3 The
disease progresses with a multisystemic involve-
ment: autonomic dysfunction causing orthostatic
hypotension, cardiac arrhythmias, gastrointestinal
dysmotility, erectile dysfunction and sphincter
disturbances.1,2 Renal involvement is common.
All patients have been found to have amyloid
deposits in the kidney, but not all had nephropa-
thy.2 FAP nephropathy has special epidemiological
features; only one-third of patients develop chronic
kidney disease (CKD) and 10 per cent progress to
CKD stage 5d.2
Without treatment, the patients die after 8–10
years, following the development of muscular atro-
phy, severe autonomic neuropathy, cachexia and
malnutrition. Because more than 90 per cent of
the mutant protein is produced by the liver, ortho-
topic liver transplantation has been proposed to
treat this disease.
Subsets of families with late onset and aged
asymptomatic patients have been identiﬁed.
Environmental and genetic factors are believed to
contribute to this variability.
Case report
A 51-year-old white female with V30M TTR gen-
etic diagnosis in January 2009, was referred to our
nephrology appointment by the Hepatic Transplant
Unit, to be evaluated for liver and kidney trans-
plant requirement.
The patient has a familial history of FAP and
CKD. Her mother died with malnutrition, inﬂam-
mation and atherosclerosis syndrome, on dialysis,
without being diagnosed for FAP. Her brother died
with muscular atrophy and malnutrition, and had
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been diagnosed with FAP. Her twin sister has CKD
of an unknown cause, and received a kidney trans-
plant; she does not have FAP symptoms and ref-
uses to receive genetic tests.
The patient has no manifestations of FAP other
than ﬁrst-degree atrioventricular block. She has a
medical history of acquired angioedema since her
forties, without any current medication.
The laboratory data revealed Hg 13.1 g/dl, WBC
6200, thrombocytes 99,000/mm3, serum creatinine
(Scr) 1.3mg/dl, sodium 137mEq/l, potassium
5.1mEq/l, calcium 9.4mg/dl, phosphorus 3.9mg/
dl, albumin 4.2 g/dl and uric acid 6.4mg/dl.
Paraprotein was negative in plasma and urine.
Urine had 10mg/dl protein and haemoglobin
(þþ) on dipstick testing, sediment revealed many
haematocytes/ﬁeld and culture was negative; 24
hours’ collection showed 1.3 g of proteinuria.
Complement study revealed normal C1-inhibitor
levels (38.2mg/dl, normal range 21–39) and
normal C1-inhibitor function (134%, nor-
mal> 68%), normal C1q levels (12.8mg/dl,
normal range 11.8–24.4), low C3 (61mg/dl,
normal range 75–140) and borderline C4 (11mg/
dl, normal range 10–34). The patient tested nega-
tive for cryoglobulinaemia.
ANAs were positive (1/320); dsDNAwas positive
(149.7U/ml, normal< 100) and anti-nucleosomes
were positive (71.3U/ml, normal< 20).
Antiphospholipid antibodies were positive, includ-
ing IgG anticardiolipin (19.8 UGPL, normal 12)
and IgG anti-b2 glycoprotein-I (12.3 USGU,
normal 12).
Ultrasound showed normal-sized and diﬀeren-
tiated kidneys, without post-mictional residue.
Creatinine clearance by DTPA was 57.6ml/min.
Despite thrombocytopenia, a skin and a renal
biopsy were performed. In the skin biopsy, lupus
band test was positive and vascular amyloid depos-
its were present. Other morphological features of
the skin biopsy were normal: there were no other
lesions like vasculitis, and nerve distribution and
appearance were normal, without atrophy, when
using Protein S100 marker (Figure 1). The kidney
biopsy had seven glomeruli, three with segmental
and difuse mesangial proliferation (Figure 2a). The
interstitium and tubules were normal, and there
were sparse amyloid deposits in the medulla. The
arteries had amyloid deposits in the media.
Immunostaining was positive for C3 (þ), C4 (þ),
C1q (þþ), IgG (þ) and IgM (þ). Anti-TTR was
positive (Figure 2b). Diagnosis of systemic lupus
erythematosus (SLE) with lupus nephritis Class II
and renal TTR amyloidosis were made.
Discussion
This is a case where three rare diseases are linked,
and this association could alter their clinical
manifestations.
Figure 1 Skin section with normal dermal nerves (anti-PS100 antibody, peroxidase immunostaining in paraffin section 40).
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Portuguese variant FAP usually manifests with
neurological abnormalities at a young age. There
are reported Portuguese cases with late-onset or
no manifestations despite genetic disease, and it
has been suggested that environmental factors con-
tribute to this phenotype variability.
Recently, it has been shown that in V30M TTR
Portuguese type, diﬀerences in penetrance are
dependent of the transmitting parent, being higher
in the case of maternal transmission.4 In addition,
another study demonstrated that mitochondrial
polymorphism eﬀect was suﬃcient to explain
higher penetrance in the case of maternal inherit-
ance of the disease.5
Variability in age of onset has also been studied.
Nylander showed that genetic variants of comple-
ment factors C3 and isotype C4A may interact with
the mutant TTR, modifying the expression and age
of onset of FAP.6 More recently, C1q and its single
nucleotide polymorphism in C1qA and C1qC, were
implicated in diﬀerent age of onset in Cypriot
patients.7
In addition to FAP, this patient suﬀers from
SLE. The involvement of complement in the aetio-
pathogenesis of SLE has been reported. Activation
of the complement system plays an important role
in tissue damage, as a consequence of immune com-
plex deposition, formed during the course of the
disease. A hereditary deﬁciency of the early compo-
nents of the classical pathway has been associated
with development of SLE: homozygous deﬁciency
of C4A and heterozygous deﬁciency of C4A and/or
C4B is relatively frequent and reported in patients
with SLE; homozygous C1q deﬁciency is also asso-
ciated with SLE, usually with severe manifest-
ations; homozygous C3 deﬁciency seldom
develops SLE.8 Nonetheless, SLE can also be an
acquired disease. The classical example is angioe-
dema: C1-inhibitor deﬁciency causes unregulated
activation of the kininogen and complement
systems, with consequent reduced serum levels of
C2 and C4, following SLE development.8 Of note
this patient has a medical history of acquired
angioedema.
In addition to FAP, neurological involvement is
also reported in SLE. Patients present with a
myriad of signs, involving the brain, spinal cord
or peripheral nervous system. Although pathogen-
esis is unknown, neurological involvement seems to
be caused by vascular disease aﬀecting small ves-
sels, namely perivascular inﬂammation or non-
inﬂammatory hyalinization. True vasculitis as the
cause for neurological dysfunction is very rare.
Vasculitis is a blood vessel inﬂammation accompa-
nied by reactive lesion of the aﬀected vessels. In
SLE, all sizes of vessels may be aﬀected, and vas-
culitis can be cutaneous or visceral, with the former
making up the majority of cases. Cutaneous vessel
involvement is usually present as punctuate lesions,
purpuric plaques, cutaneous necrosis, ulcerations
or nodules, and the deﬁnitive diagnosis is made
by biopsy. In this patient no skin lesions were
observed.
Peripheral nervous system manifestations occur
in 2–21 per cent of neuropsychiatric patients, and
antineuronal antibodies have been implicated.
Despite these numbers, there are multiple causes
of peripheral nervous system involvement, which
must be considered, evaluated and ruled out
before attributing these symptoms to SLE.
As with FAP, the most common presentation is a
distal sensorimotor neuropathy.9 Patients with
distal, symmetric, peripheral polyneuropathy can
present with a mild to severe sensory or sensori-
motor ﬁbre involvement, as numbness, dysaesthe-
sias or hypaesthesias. Nevertheless, recent studies
of skin biopsies demonstrated involvement of
small, non-myelinated aﬀerent nerve ﬁbres and
skin denervation.10 This last issue was also reported
in FAP due to Ala97Ser mutation of TTR,
Figure 2 (a) Segmental and difuse mesangial proliferation (HE 400). (b) Amyloid deposits in the media, with anti-TTR positive
(TTR 200).
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indicating that small-ﬁbre sensory neuropathy is
one of the most prevalent components of these
patients with FAP, compared with other types of
neuropathy.11 To our knowledge, no reported cases
of skin denervation were observed in Val30Met
mutations.
The skin biopsy of our patient was performed in
normal skin (without macroscopic lesions), in the
deltoid region of the left arm. There were no signs
of vasculitis, and no signs of intraepidermal nerve
ﬁbre reduction or morphological alteration. It is
important to note that our patient did not have
neurological manifestations of FAP (or SLE),
other than ﬁrst-degree atrioventricular block.
Autonomic disorders can also appear in SLE.9
We emphasise that this patient has a monozy-
gotic twin sister with a discordant clinical pheno-
type. It is likely that her sister also has late-onset
FAP. Although genetic inﬂuences are crucial to
SLE, concordance rate of the disease in monozy-
gotic twins varies between 24 and 58 per cent, indi-
cating that non-germline factors are required for
the development of the disease. Hence, we may pre-
sume that she does not have SLE or that her past
history of dialysis could decrease clinical and sero-
logical activity of the disease, a phenomenon
known as SLE burn out.
In conclusion it seems that in this particular case,
complement deﬁciency was crucial for the develop-
ment of SLE and acquired angioedema, and prob-
ably was the cause for late onset of FAP disease. In
addition, we can also suppose that FAP and SLE
could interact and change clinical course of both, as
was demonstrated in patients with AA amyloidosis
and SLE. As a result, TTR protein could be depos-
ited in lupus tissues without evidence of clinical
amyloid, and could be protective against lupus.
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